JPMorgan said in an Aug. 19 research note that Moderna and Merck’s individualized neoantigen therapy, or INT, met the primary endpoint in a phase III trial in adjuvant melanoma, with recurrence-free survival showing a significant improvement. The key secondary endpoint, distant metastasis-free survival, also came through. In the bank’s view, the outcome was in line with expectations, and the market had already priced it into Moderna shares before the announcement.
Moderna shares rose in premarket trading after the update, but JPMorgan maintained its Underweight rating and a $40 price target. Based on the $63 share price cited in the note, that target implies 36% downside. The bank’s central argument is straightforward: success in adjuvant melanoma has already been priced in, and Moderna now needs to prove that INT can reproduce that result in a broader set of indications.
Melanoma data matched JPMorgan’s prior assumptions
JPMorgan said it had previously assigned an 85% probability of success to INT’s phase III study in adjuvant melanoma. That assessment rested on two points: strong efficacy signals from phase IIb data and what the bank described as a biologically credible mechanism in cancer immunotherapy.
The trial’s primary endpoint was recurrence-free survival, while distant metastasis-free survival served as the key secondary endpoint. JPMorgan cited a melanoma specialist who described distant metastasis-free survival as 「an extremely meaningful endpoint」 and 「where the value lies」. The note said the appearance of distant metastasis often signals a much worse prognosis, and delaying or preventing it carries real clinical significance for patient quality of life.
Still, JPMorgan argued that the result itself is not a new driver for the stock. Before the announcement, Moderna’s market capitalization was already close to $25 billion, and the bank said that valuation already included expectations for INT approval in adjuvant melanoma. After risk adjustment, this indication contributes only about 3% to JPMorgan’s valuation framework.
Non-melanoma readouts are the key variable
According to the note, adjuvant melanoma is a relatively small indication within cancer immunotherapy. INT in combination with Merck’s Keytruda has shown clear clinical value, but the commercial opportunity in this setting is limited. To support a market value near $25 billion, Moderna needs INT to work in other tumor types as well.
JPMorgan said its valuation model already includes about $15 per share in risk-adjusted value tied to INT’s potential in other indications. That makes future data disclosures and follow-on trials outside melanoma the main factor for valuation from here.
Adjuvant melanoma may be the most advanced indication in the INT pipeline, but JPMorgan said it is far from the end point. The note said the broader clinical setup across other cancers will determine the ceiling for INT as a platform technology. From a biological standpoint, the logic behind individualized neoantigen therapy is not limited to melanoma. JPMorgan said the approach is theoretically applicable in tumor types with higher immunogenicity, including lung cancer, head and neck cancer, and renal cancer. But theoretical feasibility is not the same as clinical proof, and later data will matter most.
How JPMorgan arrived at the $40 target
JPMorgan’s $40 price target is based on a discounted cash flow model that uses a 10.5% weighted average cost of capital and a 0% terminal growth rate. The valuation covers Moderna’s existing commercial products along with the pipeline on a risk-adjusted basis.
The bank listed upside risks that include better-than-expected INT data in non-melanoma indications, faster product approvals, and improved vaccine demand under policy changes. Downside risks include the standard drug-development risks Moderna faces in the mRNA platform race: clinical failures, regulatory delays, and weaker-than-expected commercial uptake.
JPMorgan also said the premarket rise after the news looked more like short covering and near-term trading sentiment than a structural change in fundamentals. In its view, INT’s performance in other indications will define Moderna’s valuation ceiling. If future data show that the platform has clinical activity across more tumor types, Moderna’s valuation could be revised materially higher. If the data disappoint, part of the cross-indication value already embedded in the stock could come under pressure.
The bank kept its bearish stance. Its conclusion was that INT’s clinical value in melanoma is clear, but that value has already been fully priced in. What Moderna still has to prove is whether INT can work just as effectively in more cancer types.
The ratings, price target, earnings forecasts, and related judgments referenced here are JPMorgan views from its Aug. 19, 2026 research note and represent the firm’s position only.
